Page 1

Telix Telix Pharmaceuticals Limited ACN 616 620 369 55 Flemington Road North Melbourne Victoria , 3051 Australia ASX ANNOUNCEMENT Telix 2026 Half - Year Results : Strong Commercial Execution and Momentum in Late - Stage Pipeline Melbourne ( Australia ) and Indianapolis , IN ( U.S. ) – August 20 , 2026. Telix Pharmaceuticals Limited ( ASX : TLX , NASDAQ : TLX , " Telix " ) today announces its financial results for the period ended June 30 , 2026 . H1 2026 key results Group performance¹ : Double - digit revenue growth and gross margin improvement • • • • • • • Group revenue of US $ 477 million , up 22 % ² year - over - year , tracking in line with the upper end of full year guidance of US $ 950 million to US $ 970 million . Group gross margin of 55 % , up 2 % year - over - year , Precision Medicine gross margin of 65 % , up 1 % year - over - year , reflecting solid commercial performance , a favorable product mix and operational efficiencies . Adjusted EBITDA³ of US $ 52 million , up 146 % year - over - year reflecting strong demand across our product portfolio and initial non - refundable payment of US $ 40 million from Regeneron collaboration4 . Research & Development ( R & D ) investment of US $ 124 million , primarily directed toward advancing late - stage therapeutic and precision medicine programs , supporting the Company's strategy to build diversified revenue streams . Entered into strategic collaboration with Regeneron to jointly develop and commercialize next generation radiopharmaceutical therapies4 . Completed refinancing of existing convertible bond structure , issuing US $ 600 million of new convertible bonds due 20315 . Profit after tax of US $ 38 million includes US $ 40 million of other income received from Regeneron and finance costs of US $ 19 million , predominately related to refinancing of the convertible bonds . Generated positive operating cash flow of US $ 23 million and maintained a cash balance of US $ 252 million as of June 30 , 2026 . Executive commentary Managing Director and Group CEO , Dr. Christian Behrenbruch , stated : “ Telix delivered an outstanding first half , with strong revenue growth , market share gains and significant progress across clinical and regulatory milestones . Our strengthened balance sheet is enabling increased investment in late - stage programs , including ProstACT Global , market expansion opportunities within our precision medicine portfolio and manufacturing and supply chain capabilities that differentiate Telix . With multiple near - term catalysts , we enter the second half with strong momentum and confidence . " 1 Group performance includes Telix Precision Medicine , Telix Therapeutics and Telix Manufacturing Solutions ( TMS ) . 2 All comparisons to H1 2025 results . 3 Earnings before interest , tax , depreciation and amortization . 4 Telix ASX disclosure April 13 , 2026 . 5 Telix ASX disclosure April 14 , 2026 . 1